Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for the ...
This week’s recap unpacks how evolving exploits, malware frameworks, and cloud missteps are reshaping modern cyber defense ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback